Quantcast

Latest NovaBay Pharmaceuticals Inc. Stories

2009-10-30 08:30:00

EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia. "This model tests both the penetration of the nail as well as the effectiveness...

2009-10-28 06:30:00

EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) will hold a webcast conference call on October 30, 2009 to review preclinical data from a study of Aganocide® product candidates NVC-422 and NVC-612 in a model of onychomycosis, commonly termed nail fungus. The study data will be presented on October 31, 2009 in Philadelphia, PA at the 47th Annual Meeting of the Infectious Diseases Society of America. During the conference...

2009-10-22 06:00:00

EMERYVILLE, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) http://www.novabaypharma.com, a clinical stage company developing non-antibiotic antimicrobial compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, today announced that Thomas Paulson, Chief Financial Officer, will deliver a corporate presentation at the Bio Investor Forum 2009 being held at The Palace Hotel in San Francisco. Mr. Paulson's...

2009-10-19 06:00:00

EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, today announced that the company has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company. "We are adding Mark to our team at a critical time as our partnerships with Alcon and Galderma...

2009-09-24 09:00:00

EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY) http://www.novabaypharma.com, a clinical stage company developing non-antibiotic antimicrobial compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Maxim Group Growth Conference at 10 a.m. (ET), Tuesday, Sept. 29, 2009 at the Grand Hyatt Hotel in...

2009-09-14 13:15:00

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These two separate laboratory studies of its...

2009-09-10 05:30:00

EMERYVILLE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo. NovaBay's partner in the impetigo trial is Galderma, S.A. the world's leading...

2009-09-03 07:00:00

EMERYVILLE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY, http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Healthcare Conference at 10 a.m., Thursday, Sept. 10, 2009 at...

2009-08-24 08:00:00

EMERYVILLE, Calif., Aug. 24 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, announced today the company has received acceptance to deliver a poster presentation at the 47th Annual Meeting of the Infectious Diseases Society of America October 29 - November 1, 2009 in Philadelphia. The poster...

2009-08-21 13:39:00

EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related